Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial

@article{Onishi2017InsulinDA,
  title={Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial},
  author={Y. Onishi and K. Yamada and J. Zacho and J. Ekelund and Y. Iwamoto},
  journal={Journal of Diabetes Investigation},
  year={2017},
  volume={8},
  pages={210 - 217}
}
Insulin degludec/insulin aspart (IDegAsp) is a soluble combination of insulin degludec (70%) and insulin aspart (30%). The present exploratory trial investigated the safety of switching unit‐to‐unit from twice‐daily basal or pre‐mix insulin to twice‐daily IDegAsp in Japanese patients with type 2 diabetes. 
3 Citations

Paper Mentions

Interventional Clinical Trial
This trial is conducted in Japan. The aim of this clinical trial is to investigate the safety (with emphasis on hypoglycaemia) after switching from long-acting insulin analogue… Expand
ConditionsDiabetes, Diabetes Mellitus, Type 2
InterventionDrug

References

SHOWING 1-10 OF 24 REFERENCES
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
  • 22
  • PDF
...
1
2
3
...